MET and non-small cell lung carcinoma: Most prominently in NSCLC, MET exon 14 (METex14) skipping mutations are characterized by the fusion of exons 13 and 15, which ultimately impairs receptor degradation, thus overactivating the MET-mediated signaling [102].